Kumasi Center for Collaborative Research (KCCR) >
Please use this identifier to cite or link to this item:
|Title: ||Substandard artemisinin-based antimalarial medicines in licensed retail pharmaceutical outlets in Ghana|
|Authors: ||El-Duah, M.|
|Keywords: ||Artemisinin-based combination therapy|
|Issue Date: ||Sep-2012|
|Publisher: ||Journal of Vector Borne Diseases|
|Citation: ||J Vector Borne Dis 49, September 2012, pp. 131–139|
|Abstract: ||The artemisinin-based antimalarial medicines are first line medicines in the treatment
of severe and uncomplicated falciparum malaria. Numerous brands of these medicines manufactured in various
countries are available in the Ghanaian market. The study was aimed at evaluating the authenticity and quality
of selected brands of artemisinin-based antimalarial medicines marketed in Ghana.
Methods: In all, 14 artemisinin-based antimalarial medicines were purchased from pharmacies (P) and licensed
chemical shops (LCSs) in the Kumasi metropolis, Ghana. Simple field tests based on colorimetry and thin layer
chromatography were employed in determining the authenticity of the samples. Important quality assessment
tests, namely uniformity of mass, crushing strength, disintegration time, and the percentage content of active
pharmaceutical ingredients (APIs) were determined.
Results: All the brands tested contained the stipulated APIs. Artesunate tablet AT2 failed the uniformity of mass
test while artesunate tablets AT3 & AT4 as well as amodiaquine tablets AM4 & AM6 failed the crushing strength
test. All the six artemether-lumefantrine tablet brands passed the uniformity of mass, crushing strength and
disintegration tests. Only artemether-lumefantrine tablet brand AL1 contained the correct amount of the drugs.
The other 13 artemisinin products contained either a lower (underdose) or higher (overdose) amount of the
specified drug. Artesunate monotherapy tablets were readily available in pharmacies and licensed chemical
Interpretation & conclusion: All the artemisinin-based medicines tested (except AL1) were of substandard
quality. The results demonstrate the need for continuous monitoring and evaluation of the quality of artemisininbased
antimalarials in the Ghanaian market. Also, the practice of artemisinin antimalarial monotherapy is prevalent
in Ghana. Determined efforts should, therefore, be made to eradicate the practice to prevent the development of
resistance to the artemisinins.|
|Description: ||Article published in J Vector Borne Dis 49, September 2012, pp. 131–139|
|Appears in Collections:||Publications|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.